+
Home
+
Contact
Profile
Management
Directors
Mission & Values
Awards & Recognition
Contact Us
Directions
Overview
Somatic Cell Therapies »
Overview
LG690 (GVHD)
LG768 (CLL)
Stem Cell Therapies »
Overview
LG631 (Glioma)
LG889 (Hemophilia)
Vaccines »
Overview
LG611 (Pandemic Flu)
LG811 (Seasonal Flu)
Protein Therapeutics »
Overview
LG747 (Anemia)
LG888 (Hemophilia)
Contact Us
Clinical Trials
Trials open for enrollment
Patient's Library »
Disease Information
What are clinical trials?
Glossary
Business Strategy
Business Model
Therapeutic Pipeline
OBM Business Unit »
Overview
Invitrogen
Thermo Fisher Scientific
Partnerships
Intellectual Property
Calendar of Events
Contact Us
Press Releases
Media Kit
Contact Us
Why Lentigen?
Positions Open
Contact Us
Scientific American's Steve Mirsky talks to Boro Dropulic about
converting viruses into disease fighters.
Listen to this podcast
.
Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement [pdf]
Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza [pdf]
Lentigen Corporation and The United States Army Agree to Contract [pdf]
© Copyright 2008 Lentigen Corp. All Rights Reserved.
+
Privacy Policy
+
Terms of Use
Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement [pdf]